Your browser doesn't support javascript.
loading
International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia.
Watts, Gerald F; Jones, Laney K; Sarkies, Mitchell N; Pang, Jing; Gidding, Samuel S; Libby, Peter; Santos, Raul D.
Afiliação
  • Watts GF; School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
  • Jones LK; Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia.
  • Sarkies MN; Department of Genomic Health, Geisinger, Danville PA, USA.
  • Pang J; School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Gidding SS; School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
  • Libby P; Department of Genomic Health, Geisinger, Danville PA, USA.
  • Santos RD; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.
Glob Heart ; 19(1): 12, 2024.
Article em En | MEDLINE | ID: mdl-38273993
ABSTRACT
Familial hypercholesterolaemia (FH), a common monogenic disorder, is a preventable cause of premature coronary artery disease and death. Up to 35 million people worldwide have FH, but most remain undetected and undertreated. Several clinical guidelines have addressed the gaps in care of FH, but little focus has been given to implementation science and practice. The International Atherosclerosis Society (IAS) has developed an evidence-informed guidance for the detection and management of patients with FH, supplemented with implementation strategies to optimize contextual models of care. The guidance is partitioned into detection, management and implementation sections. Detection deals with screening, diagnosis, genetic testing and counselling. Management includes risk stratification, treatment of adults and children with heterozygous and homozygous FH, management of FH during pregnancy, and use of lipoprotein apheresis. Specific and general implementation strategies, guided by processes specified by the Expert Recommendations for Implementing Change taxonomy, are provided. Core generic implementation strategies are given for improving care. Nation-specific cholesterol awareness campaigns should be utilized to promote better detection of FH. Integrated models of care should be underpinned by health policy and adapted to meet local, regional and national needs. Clinical centres of excellence are important for taking referrals from the community. General practitioners should work seamlessly with multidisciplinary teams. All health-care providers must receive training in essential skills for caring for patients and families with FH. Management should be supported by shared decision-making and service improvement driven by patient-reported outcomes. Improvements in services require sharing of existing resources that can support care. Advocacy should be utilized to ensure sustainable funding. Digital health technologies and clinical quality registries have special value. Finally, academic-service partnerships need to be developed to identify gaps in care and set priorities for research. This new IAS guidance on FH complements the recent World Heart Federation Cholesterol Roadmap.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Hiperlipoproteinemia Tipo II Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Adult / Child / Female / Humans / Pregnancy Idioma: En Revista: Glob Heart Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Hiperlipoproteinemia Tipo II Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Adult / Child / Female / Humans / Pregnancy Idioma: En Revista: Glob Heart Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália